< Back to previous page
Researcher
Philip Van Damme
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Behavioural neuroscience
- Disciplines (KU Leuven):Neurological and neuromuscular diseases
- See also: Philip Van Damme (Flanders Institute for Biotechnology)
Affiliations
- Van Den Bosch Lab (Research group)
Member
From1 Jan 2017 → Today - Laboratory for Neurobiology (VIB-KU Leuven) (Lab)
Member
From1 Jan 2012 → Today - Research Group Experimental Neurology (Division)
Member
From1 Oct 2000 → 31 Dec 2011
Projects
1 - 10 of 49
- Towards mechanistic biomarkers for amyotrophic lateral sclerosisFrom1 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Mapping the microglial heterogeneity in C9orf72-ALS and sporadic ALS using single cell profilingFrom1 Nov 2023 → TodayFunding: BOF - postdoctoral mandates
- A multi-modal and longitudinal approach to study the neurobiological underpinnings of disease onset and progression in genetic ALS variants: from presymptomatic to symptomatic disease stages.From1 Oct 2023 → TodayFunding: FWO junior postdoctoral fellowship
- HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutationsFrom19 Apr 2023 → 31 Dec 2023Funding: Foundations, funds and other with scientific goal
- Measuring brain activation non-invasively in freely moving healthy and neuropsychiatric human populations using functional near-infrared spectroscopy (fNIRS)From1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Investigating the role of cilia dysfunction in Amyotrophic Lateral SclerosisFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Mechanisms of motor neuron degeneration in amyotrophic lateral sclerosis (ALS): cell death pathways and/or aberrant communication between cell body and neuromuscular junctionsFrom1 Oct 2022 → TodayFunding: BOF - projects
- A multi-modal approach to study C9orf72-mediated diseaseFrom16 May 2022 → 15 May 2023Funding: BOF - postdoctoral mandates
- Biomarkers in asymptomatic carriers of ALS-related mutationsFrom1 Apr 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding lysosomal dysfunction in the frontotemporal dementiaamyotrophic lateral sclerosis spectrum of neurodegenerative disorders.From1 Jan 2022 → TodayFunding: FWO research project (including WEAVE projects)
Publications
261 - 270 of 340
- Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study(2014)
Authors: Robin Lemmens, An Goris, Philip Van Damme, Wim Robberecht
Pages: 2420 - Development of a disease severity scale for Becker muscular dystrophy(2014)
Authors: JC van den Bergen, BHA Wokke, Philip Van Damme, AJ van der Kooi, J De Bleecker, P De Jonghe, JJ Verschuuren
Pages: 795 - 795 - Psychometric properties of ACTIVLIM in 2-year cross sectional records of the Belgian Neuromuscular Disease Registry(2014)
Authors: CS Batcho, PYK Van den Bergh, Philip Van Damme, A Roy, M Penta
Pages: 905 - 906 - The Belgian Neuromuscular Disease Registry, results of the 2012 data(2014)
Authors: A Roy, P Van den Bergh, Philip Van Damme, V Van Casteren
Pages: 893 - 893 - Interplay between Progranulin and TDP-43 in the pathogenesis of Amyotrophic Lateral Sclerosis(2014)
Authors: Philip Van Damme, Wim Robberecht
- Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis(2014)
Authors: Wim Robberecht, Philip Van Damme
Pages: 344 - 50 - Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration(2014)
Authors: Mathieu Vandenbulcke, Philip Van Damme, Wim Robberecht, Rik Vandenberghe
Pages: 397 - 410 - Peripheral progranulin levels do not reflect brain progranulin levels(2014)
Authors: Philip Van Damme
Pages: 521 - 524 - Developments in treatments for amyotrophic lateral sclerosis via intracerebroventricular or intrathecal delivery(2014)
Authors: Philip Van Damme, Wim Robberecht
Pages: 955 - 63 - C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genome-wide meta-analysis(2014)
Authors: Philip Van Damme, Wim Robberecht
Pages: 120 - 33